drugset

drugset / Trial / NCT04602598

Zanubrutinib in Patients With IgG4-Related Disease

NCT04602598 ↗

Phase 2 Completed 10 enrolled Matthew C. Baker Stanford University · collab

NaSingle-groupOpen-labelTreatment

Summary

The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease

Timeline

Start: 2022-08-01
Primary completion: 2025-02-11
Completion: 2025-04-03

Outcome

Met primary endpoint

registry analysis (other test); Zanubrutinib; p < 0.001; Wilcoxon signed-rank test; NCT04602598 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zanubrutinib	Small molecule	80 mg	Oral

Indications